New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
15:28 EDTMBIIMarrone Bio says facility approved for USDA loan guarantee
Marrone Bio Innovations announced the U.S. Department of Agriculture Business and Industry Guaranteed Loan program approved a guarantee for a $10M loan financing. The loan is now only subject to completion of related bank documentation. The funds will be used to expand the production capacity of the MBI manufacturing plant in Bangor, MI.
News For MBII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
10:00 EDTMBIIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Achillion (ACHN) downgraded on valuation at JMP Securities... Ashland (ASH) downgraded to Equal-Weight from Overweight at First Analysis... Bank of Nova Scotia (BNS) downgraded to Underperform from Neutral at BofA/Merrill... Braskem (BAK) downgraded to Neutral from Overweight at JPMorgan... Comerica (CMA) downgraded to Underperform at Baird... Crestwood Midstream (CMLP) downgraded to Neutral from Buy at Ladenburg... Fifth Third (FITB) downgraded to Neutral from Outperform at Baird... Keurig Green Mountain (GMCR) downgraded to Hold from Buy at Argus... Keysight Technologies (KEYS) downgraded to Neutral from Outperform at Baird... Leju (LEJU) downgraded to Underperform from Buy at CLSA... Marrone Bio (MBII) downgraded to Hold from Buy at Jefferies... Southwest (LUV) downgraded to Neutral from Buy at Buckingham... SunTrust (STI) downgraded to Market Perform from Outperform at Keefe Bruyette... Western Alliance (WAL) downgraded to Market Perform from Outperform at Keefe Bruyette.
08:04 EDTMBIIMarrone Bio downgraded to Hold from Buy at Jefferies
Jefferies downgraded Marrone Bio Innovations to Hold with a $2.25 price target after the company said it is evaluating restatements.
May 18, 2015
17:09 EDTMBIIMarrone Bio evaluating the necessity, nature and scope of any restatements
Subscribe for More Information
16:55 EDTMBIIMarrone Bio provides update on NASDAQ matters
Subscribe for More Information
May 12, 2015
17:17 EDTMBIIMarrone Bio to delay filing Form 10-Q
Marrone Bio Innovations announced that on May 6, as anticipated, the company was notified by the Listing Qualifications Staff of The NASDAQ Stock Market that, based upon the company’s continued non-compliance with NASDAQ’s filing requirements under NASDAQ Listing Rule 5250(c)(1), the uncertainty of the company’s time frame to file all its required periodic reports and its expectation that it would not file all periodic reports with the SEC by May 13, the termination of the exception period previously granted by the Staff, the company’s securities were subject to delisting unless the Company timely requests a hearing before the NASDAQ Listing Qualifications Panel. In addition, the company announced that it does not expect to file on a timely basis its Quarterly Report on Form 10-Q for the three months ended March 31, resulting in further noncompliance with NASDAQ Listing Rule 5250(c)(1). The company intends to timely request a hearing before the Panel, at which hearing the company will present its plan to evidence compliance with NASDAQ’s filing requirement and request an extension within which to do so. In accordance with the NASDAQ Listing Rules, the Panel has the authority to continue the company’s listing on NASDAQ pursuant to an exception to the filing requirement through as late as November 2. The company’s common stock will continue to trade on The NASDAQ Global Market under the symbol “MBII” pending the completion of the hearing process and the expiration of any extension period granted by the Panel.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use